Table 2.
Pre- and post-vaccine determinations: mean specific antibodies increases and avidities of IgG and IgA against the PRP. Also shown are the percentage of bacteria (Haemophilus influenzae type b) opsonophagocitosed by PMN in the three groups studied
| Variable | Cases (n = 33) | HIV-1 positive controls (n = 33) | P* | Healthy controls (n = 27) | P† |
|---|---|---|---|---|---|
| Antibodies | |||||
| IgG (µg/ml) | |||||
| Prevaccine | 1·88 (±4·52) | 1·22 (±3·99) | 1·46 (±4·39) | ||
| Post-vaccine | 2·82 (±6·71) | 2·88 (±6) | 5·86 (±6·87) | ||
| Mean increase | 1·59 (0·56–14·99) | 3·94 (0·83–17·88) | <0·001 | 13·30 (0·90–88·7) | <0·001 |
| IgG2 (U/ml) | |||||
| Prevaccine | 39·9 (±84·5) | 36·5 (±99·9) | 107·9 (±105·9) | ||
| Post-vaccine | 46·2 (±85·1) | 67·3 (±140·5) | 166·9 (±113·6) | ||
| Mean increase | 1·43 (0·5–5) | 2·76 (0·5–13·25) | 0·05 | 2·64 (0·68–15) | 0·05 |
| IgA (U/ml) | |||||
| Prevaccine | 67·7 (±90·7) | 85·7 (±122·7) | 108·2 (±151·5) | ||
| Post-vaccine | 92·8 (±121·4) | 169·1 (±185·3) | 476·4 (±281·8) | ||
| Mean increase | 1·62 (0·5–8·17) | 8·75 (0·46–154) | <0·01 | 51·11 (0·73–623) | <0·001 |
| IgG avidity | |||||
| Prevaccine | 1·47 (1–3) | 1·24 (1–3) | n.s. | 1·44 (1–2) | n.s. |
| Post-vaccine | 1·52 (1–3) | 1·33 (1–2) | n.s. | 1·93 (1–4) | n.s. |
| IgA avidity | |||||
| Prevaccine | 1·87 (1–4) | 1·82 (1–4) | n.s. | 1·18 (1–2) | n.s. |
| Post-vaccine | 1·69 (1–3) | 1·67 (1–4) | n.s. | 1·41 (1–2) | n.s. |
| Opsonophagocytosis | |||||
| H. influenzae b | |||||
| Prevaccine | 27·8 (±11·6)% | 34·3 (±13·8)% | n.s. | 27·6 (±12·1)% | n.s. |
| Post-vaccine | 25·5 (±15·4)% | 31 (±11·8)% | n.s. | 34·2 (±8·9)% | n.s.‡ |
*
Cases versus HIV-1 seropositive controls.
†
Seronegative controls versus all HIV-1-infected patients considered as a whole group.
‡
Statistical significance (P < 0·05) only between HIV-1 seropositive controls vs. seronegative subjects.